Press coverage about Covance (NYSE:CVD) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Covance earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the healthcare company an impact score of 47.4312093301209 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Covance (NYSE CVD) remained flat at $$107.07 during trading hours on Friday. The firm has a market capitalization of $6,060.00 and a PE ratio of 33.05.
COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.com-unik.info/2018/01/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-covance-cvd-share-price.html.
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with MarketBeat.com's FREE daily email newsletter.